FDA Approves First Ophthalmic Bevacizumab, Marking a Milestone in Wet AMD Treatment
"After two decades of off-label use, the FDA’s approval of Lytenava for wet AMD signifies a crucial shift toward formalized safety and quality oversight for a widely used treatment, though…